DOI QR코드

DOI QR Code

Outcomes of stereotactic body radiotherapy for unresectable primary or recurrent cholangiocarcinoma

  • Jung, Da Hoon (Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences) ;
  • Kim, Mi-Sook (Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences) ;
  • Cho, Chul Koo (Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences) ;
  • Yoo, Hyung Jun (Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences) ;
  • Jang, Won Il (Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences) ;
  • Seo, Young Seok (Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences) ;
  • Paik, Eun Kyung (Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences) ;
  • Kim, Kum Bae (Department of Radiation Oncology, Korea Institute of Radiological & Medical Sciences) ;
  • Han, Chul Ju (Department of Internal Medicine, Korea Institute of Radiological & Medical Sciences) ;
  • Kim, Sang Bum (Department of Surgical Oncology, Korea Institute of Radiological & Medical Sciences)
  • Received : 2014.05.30
  • Accepted : 2014.08.13
  • Published : 2014.09.30

Abstract

Purpose: To report the results of stereotactic body radiotherapy (SBRT) for unresectable primary or recurrent cholangiocarcinoma. Materials and Methods: From January 2005 through August 2013, 58 patients with unresectable primary (n = 28) or recurrent (n = 30) cholangiocarcinoma treated by SBRT were retrospectively analyzed. The median prescribed dose was 45 Gy in 3 fractions (range, 15 to 60 Gy in 1-5 fractions). Patients were treated by SBRT only (n = 53) or EBRT + SBRT boost (n = 5). The median tumor volume was 40 mL (range, 5 to 1,287 mL). Results: The median follow-up duration was 10 months (range, 1 to 97 months). The 1-year, 2-year overall survival rates, and median survival were 45%, 20%, and 10 months, respectively. The median survival for primary group and recurrent group were 5 and 13 months, respectively. Local control rate at 1-year and 2-year were 85% and 72%, respectively. Disease progression-free survival rates at 1-year and 2-year were 26% and 23%, respectively. In univariate analysis, ECOG performance score (0-1 vs. 2-3), treatment volume (<50 vs. ${\geq}50mL$), and pre-SBRT CEA level (<5 vs. ${\geq}5ng/mL$) were significant in overall survival rate. In multivariate analysis, ECOG score (p = 0.037) and tumor volume (p = 0.030) were statistically significant. In the recurrent tumor group, patients with >12 months interval from surgery to recurrence showed statistically significant higher overall survival rate than those with ${\leq}12$ months (p = 0.026). Six patients (10%) experienced ${\geq}$grade 3 complications. Conclusion: SBRT can be considered as an effective local modality for unresectable primary or recurrent cholangiocarcinoma.

Keywords

References

  1. Tan JC, Coburn NG, Baxter NN, Kiss A, Law CH. Surgical management of intrahepatic cholangiocarcinoma: a population-based study. Ann Surg Oncol 2008;15:600-8. https://doi.org/10.1245/s10434-007-9627-x
  2. Cunningham SC, Choti MA, Bellavance EC, Pawlik TM. Palliation of hepatic tumors. Surg Oncol 2007;16:277-91. https://doi.org/10.1016/j.suronc.2007.08.010
  3. Barney BM, Olivier KR, Miller RC, Haddock MG. Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma. Radiat Oncol 2012;7:67. https://doi.org/10.1186/1748-717X-7-67
  4. Crane CH, Macdonald KO, Vauthey JN, et al. Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys 2002;53:969-74. https://doi.org/10.1016/S0360-3016(02)02845-6
  5. Alden ME, Mohiuddin M. The impact of radiation dose in combined external beam and intraluminal Ir-192 brachytherapy for bile duct cancer. Int J Radiat Oncol Biol Phys 1994;28:945-51. https://doi.org/10.1016/0360-3016(94)90115-5
  6. Deodato F, Clemente G, Mattiucci GC, et al. Chemoradiation and brachytherapy in biliary tract carcinoma: long-term results. Int J Radiat Oncol Biol Phys 2006;64:483-8. https://doi.org/10.1016/j.ijrobp.2005.07.977
  7. Ben-David MA, Griffith KA, Abu-Isa E, et al. External-beam radiotherapy for localized extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2006;66:772-9. https://doi.org/10.1016/j.ijrobp.2006.05.061
  8. Ben-Josef E, Normolle D, Ensminger WD, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 2005;23:8739-47. https://doi.org/10.1200/JCO.2005.01.5354
  9. Chen YX, Zeng ZC, Tang ZY, et al. Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients. BMC Cancer 2010;10:492. https://doi.org/10.1186/1471-2407-10-492
  10. Shin HS, Seong J, Kim WC, et al. Combination of external beam irradiation and high-dose-rate intraluminal brachytherapy for inoperable carcinoma of the extrahepatic bile ducts. Int J Radiat Oncol Biol Phys 2003;57:105-12. https://doi.org/10.1016/S0360-3016(03)00410-3
  11. Tse RV, Hawkins M, Lockwood G, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008;26:657-64. https://doi.org/10.1200/JCO.2007.14.3529
  12. Kopek N, Holt MI, Hansen AT, Hoyer M. Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol 2010;94:47-52. https://doi.org/10.1016/j.radonc.2009.11.004
  13. Polistina FA, Guglielmi R, Baiocchi C, et al. Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience. Radiother Oncol 2011;99:120-3. https://doi.org/10.1016/j.radonc.2011.05.016
  14. Kim JS, Kim JS, Kim SY, Kim Ki, Cho MJ. Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2003;55:1247-53. https://doi.org/10.1016/S0360-3016(02)04401-2
  15. Yahara K, Ohguri T, Imada H, Yamaguchi S, Terashima H, Korogi Y. Cancer of the pelvis: definitive three-dimensional conformal radiotherapy for patients with isolated recurrence in the paraaortic lymph nodes. J Radiat Res 2012;53:735-41. https://doi.org/10.1093/jrr/rrs042
  16. Maneo A, Landoni F, Cormio G, et al. Concurrent carboplatin/5- fluorouracil and radiotherapy for recurrent cervical carcinoma. Ann Oncol 1999;10:803-7. https://doi.org/10.1023/A:1008356010556
  17. Sommers GM, Grigsby PW, Perez CA, et al. Outcome of recurrent cervical carcinoma following definitive irradiation. Gynecol Oncol 1989;35:150-5. https://doi.org/10.1016/0090-8258(89)90033-4

Cited by

  1. Outcomes for Patients with Recurrent Intrahepatic Cholangiocarcinoma After Surgery vol.23, pp.13, 2014, https://doi.org/10.1245/s10434-016-5454-2
  2. Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma vol.122, pp.9, 2016, https://doi.org/10.1002/cncr.29692
  3. Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma vol.1, pp.4, 2014, https://doi.org/10.1016/j.adro.2016.10.008
  4. Monitoring outcomes in intrahepatic cholangiocarcinoma patients following hepatic resection vol.3, pp.4, 2014, https://doi.org/10.2217/hep-2016-0009
  5. Clinical Outcomes of Salvage Chemoradiotherapy for Locally Recurrent Biliary Tract Cancer vol.103, pp.4, 2014, https://doi.org/10.5301/tj.5000666
  6. Comprehensive management of cholangiocarcinoma: Part II. Treatment vol.6, pp.2, 2017, https://doi.org/10.18528/gii1500342
  7. Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma vol.17, pp.None, 2014, https://doi.org/10.1186/s12885-017-3788-1
  8. Salvage radiotherapy for locoregionally recurrent extrahepatic bile duct cancer after radical surgery vol.90, pp.1080, 2017, https://doi.org/10.1259/bjr.20170308
  9. CyberKnife Stereotactic Radiosurgery for Cholangiocarcinoma vol.57, pp.10, 2014, https://doi.org/10.2169/internalmedicine.9572-17
  10. Cholangiocarcinoma: Treatment, Outcomes, and Nutrition Overview for Oncology Nurses vol.22, pp.4, 2014, https://doi.org/10.1188/18.cjon.e97-e102
  11. Emerging treatment options for cholangiocarcinoma vol.6, pp.9, 2014, https://doi.org/10.1080/21678707.2018.1476235
  12. Protocol for the STRONG trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma, a phase I feasibility study vol.8, pp.10, 2014, https://doi.org/10.1136/bmjopen-2017-020731
  13. Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: a meta-analysis and systematic review vol.195, pp.2, 2019, https://doi.org/10.1007/s00066-018-1367-2
  14. Stereotactic body radiation therapy in cholangiocarcinoma: a systematic review vol.92, pp.1097, 2014, https://doi.org/10.1259/bjr.20180688
  15. Radiation therapy for extrahepatic bile duct cancer: Current evidences and future perspectives vol.7, pp.11, 2019, https://doi.org/10.12998/wjcc.v7.i11.1242
  16. Stereotactic Body Radiation Therapy for Cholangiocarcinoma: Optimizing Locoregional Control With Elective Nodal Irradiation vol.5, pp.1, 2014, https://doi.org/10.1016/j.adro.2019.08.003
  17. Clinical Outcomes Using Magnetic Resonance–Guided Stereotactic Body Radiation Therapy in Patients With Locally Advanced Cholangiocarcinoma vol.5, pp.2, 2014, https://doi.org/10.1016/j.adro.2019.09.008
  18. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity vol.146, pp.9, 2014, https://doi.org/10.1007/s00432-020-03285-9
  19. Recurrent Intrahepatic Cholangiocarcinoma - Review vol.11, pp.None, 2014, https://doi.org/10.3389/fonc.2021.776863
  20. Stereotactic radiotherapy in intrahepatic cholangiocarcinoma: A systematic review vol.15, pp.2, 2014, https://doi.org/10.3892/mco.2021.2314
  21. Stereotactic Body Radiation Therapy after Chemotherapy for Unresectable Perihilar Cholangiocarcinoma: The STRONG Trial, a Phase I Safety and Feasibility Study vol.13, pp.16, 2014, https://doi.org/10.3390/cancers13163991